Third-line treatment in metastatic renal cell carcinoma and bone metastases

od Heng, Daniel Y. C.
Izdano u Can Urol Assoc J (2015)

The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma

od Heng, Daniel Y.C.
Izdano u Can Urol Assoc J (2016)

Contemporary Treatment of Metastatic Renal Cell Carcinoma

od Stukalin, Igor, Alimohamed, Nimira, Heng, Daniel Y.C.
Izdano u Oncol Rev (2016)

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

od Ruiz-Morales, Jose Manuel, Heng, Daniel Y.C.
Izdano u Ther Adv Urol (2016)

Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions

od Heng, Daniel Y.C., Kollmannsberger, Christian, Chi, Kim N.
Izdano 2010

Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer

od Tang, Patricia A., Heng, Daniel Y. C., Choueiri, Toni K.
Izdano 2011

Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies

od Yip, Steven M., Heng, Daniel Y.C., Tang, Patricia A.
Izdano u J Kidney Cancer VHL (2016)

Personalized Management of Advanced Kidney Cancer

od Graham, Jeffrey, Heng, Daniel Y. C., Brugarolas, James, Vaishampayan, Ulka
Izdano u Am Soc Clin Oncol Educ Book (2018)

In Reply

od de Velasco, Guillermo, Culhane, Aedín C., Heng, Daniel Y.C., Signoretti, Sabina, Choueiri, Toni K.
Izdano u Oncologist (2017)

Disease characteristics and survival outcomes of extragonadal primary germ cell tumour in two Canadian tertiary cancer centres

od Ko, Jenny J., Asif, Tehmina, Li, Haocheng, Alimohamed, Nimira, Nguyen, Phuong Thao, Heng, Daniel Y.C.
Izdano u Can Urol Assoc J (2016)

Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma

od McKay, Rana R., Lin, Xun, Perkins, Julia J., Heng, Daniel Y. C., Simantov, Ronit, Choueiri, Toni K.
Izdano 2014

Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma

od Lalani, Aly-Khan A., Bakouny, Ziad, Farah, Subrina, Donskov, Frede, Dudani, Shaan, Heng, Daniel Y. C., Choueiri, Toni K.
Izdano u JAMA Oncol (2021)

A Randomized Phase II Study of AGS‐16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma

od Kollmannsberger, Christian, Choueiri, Toni K., Heng, Daniel Y.C., George, Saby, Jie, Fei, Croitoru, Ruslan, Poondru, Srinivasu, Thompson, John A.
Izdano u Oncologist (2021)

Renal cell carcinoma

od Hsieh, James J., Purdue, Mark P., Signoretti, Sabina, Swanton, Charles, Albiges, Laurence, Schmidinger, Manuela, Heng, Daniel Y., Larkin, James, Ficarra, Vincenzo
Izdano u Nat Rev Dis Primers (2017)

Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies

od Heng, Daniel Y., Signorovitch, James, Swallow, Elyse, Li, Nanxin, Zhong, Yichen, Qin, Paige, Zhuo, Daisy Y., Wang, Xufang, Park, Jinhee, Stergiopoulos, Sotirios, Kollmannsberger, Christian
Izdano u PLoS One (2014)

A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer

od Clayton, Ravinder, Wu, Jackson, Heng, Daniel Y., North, Scott A., Emmenegger, Urban, Hotte, Sebastien, Chi, Kim, Zielinski, Rob, Al-Shamsi, Humaid, Chen, Leo, Eigl, Bernhard
Izdano 2014

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial

od Ristau, Benjamin T., Manola, Judi, Haas, Naomi B., Heng, Daniel Y. C., Messing, Edward M., Wood, Christopher G., Kane, Christopher J., DiPaola, Robert S., Uzzo, Robert G.
Izdano u J Urol (2017)

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

od Sander, Michael S., Stukalin, Igor, Vallerand, Isabelle A., Goutam, Siddhartha, Ewanchuk, Benjamin W., Meyers, Daniel E., Pabani, Aliyah, Morris, Don G., Heng, Daniel Y. C., Cheng, Tina
Izdano u Cancer Med (2021)

Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy

od Heng, Daniel Y. C., Xie, Wanling, Bjarnason, Georg A., Vaishampayan, Ulka, Tan, Min-Han, Knox, Jennifer, Donskov, Frede, Wood, Lori, Kollmannsberger, Christian, Rini, Brian I., Choueiri, Toni K.
Izdano 2010

Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

od Choueiri, Toni K., Lim, Zita Dubauskas, Hirsch, Michelle S., Tamboli, Pheroze, Jonasch, Eric, McDermott, David F., Cin, Paola Dal, Corn, Paul, Vaishampayan, Ulka, Heng, Daniel Y.C., Tannir, Nizar M.
Izdano u Cancer (2010)